Regeneron Pharmaceuticals (REGN) Operating Leases (2022 - 2025)

Regeneron Pharmaceuticals' Operating Leases history runs 4 years deep, the most recent figure standing at $986.8 million for Q4 2025.

• In Q4 2025, Operating Leases rose 3.39% year-over-year to $986.8 million; the TTM figure through Dec 2025 stood at $986.8 million (up 3.39% YoY), while the FY2025 annual figure was $986.8 million, up 3.39% from the prior year.
• Operating Leases was $986.8 million for Q4 2025 at Regeneron Pharmaceuticals, up from $954.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $986.8 million in Q4 2025 to a low of $788.2 million in Q4 2022.
• Historically, Operating Leases has averaged $884.3 million across 4 years, with a median of $881.0 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Operating Leases grew 2.47% in 2023, then gained 18.16% in 2024.
• A 4-year view of Operating Leases shows it stood at $788.2 million in 2022, then increased by 2.47% to $807.7 million in 2023, then increased by 18.16% to $954.4 million in 2024, then climbed by 3.39% to $986.8 million in 2025.
• The last three Operating Leases figures came in at $986.8 million (Q4 2025), $954.4 million (Q4 2024), and $807.7 million (Q4 2023), per Business Quant data.